Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Lineage Cell Therapeutics Inc is a biotechnology business based in the US. Lineage Cell Therapeutics shares (LCTX) are listed on the NYSE MKT and all prices are listed in US Dollars. Lineage Cell Therapeutics employs 49 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.35|
|52-week range||$1.01 - $3.13|
|50-day moving average||$2.44|
|200-day moving average||$2.56|
|Wall St. target price||$6.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.08|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||3.07%|
|1 month (2021-09-24)||-8.56%|
|3 months (2021-07-26)||-10.98%|
|6 months (2021-04-26)||-9.62%|
|1 year (2020-10-23)||86.51%|
|2 years (2019-10-25)||175.79%|
|3 years (2018-10-25)||16.92%|
|5 years (2016-10-25)||3.5|
|Revenue TTM||$1.8 million|
|Gross profit TTM||$1.4 million|
|Return on assets TTM||-13.19%|
|Return on equity TTM||-10.82%|
|Market capitalisation||$393.5 million|
TTM: trailing 12 months
There are currently 8.8 million Lineage Cell Therapeutics shares held short by investors – that's known as Lineage Cell Therapeutics's "short interest". This figure is 15.6% up from 7.6 million last month.
There are a few different ways that this level of interest in shorting Lineage Cell Therapeutics shares can be evaluated.
Lineage Cell Therapeutics's "short interest ratio" (SIR) is the quantity of Lineage Cell Therapeutics shares currently shorted divided by the average quantity of Lineage Cell Therapeutics shares traded daily (recently around 965155.81140351). Lineage Cell Therapeutics's SIR currently stands at 9.12. In other words for every 100,000 Lineage Cell Therapeutics shares traded daily on the market, roughly 9120 shares are currently held short.
However Lineage Cell Therapeutics's short interest can also be evaluated against the total number of Lineage Cell Therapeutics shares, or, against the total number of tradable Lineage Cell Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lineage Cell Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Lineage Cell Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0699% of the tradable shares (for every 100,000 tradable Lineage Cell Therapeutics shares, roughly 70 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Lineage Cell Therapeutics.
Find out more about how you can short Lineage Cell Therapeutics stock.
We're not expecting Lineage Cell Therapeutics to pay a dividend over the next 12 months.
Lineage Cell Therapeutics's shares were split on a 3:1 basis on 30 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Lineage Cell Therapeutics shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Lineage Cell Therapeutics shares which in turn could have impacted Lineage Cell Therapeutics's share price.
Over the last 12 months, Lineage Cell Therapeutics's shares have ranged in value from as little as $1.01 up to $3.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Lineage Cell Therapeutics's is 1.8317. This would suggest that Lineage Cell Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product for the treatment of facial lipoatrophy. In addition, the company offers various therapeutic products for the treatment of oncology, and neurological diseases and disorders, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.